Edition:
United States

Vanda Pharmaceuticals Inc (VNDA.OQ)

VNDA.OQ on NASDAQ Stock Exchange Global Market

14.50USD
3:59pm EST
Change (% chg)

$-0.50 (-3.33%)
Prev Close
$15.00
Open
$15.00
Day's High
$15.00
Day's Low
$14.45
Volume
199,384
Avg. Vol
174,858
52-wk High
$18.00
52-wk Low
$6.95

VNDA.OQ

Chart for VNDA.OQ

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company's product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostat... (more)

Overall

Beta: 1.47
Market Cap(Mil.): $659.20
Shares Outstanding(Mil.): 43.95
Dividend: --
Yield (%): --

Financials

  VNDA.OQ Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.42 -- --
ROI: -11.19 -4.07 13.03
ROE: -13.63 4.71 14.17

BRIEF-Point72 Asset Management reports 5 pct passive stake in Vanda Pharmaceuticals as of Feb 15 - SEC Filing

* Point72 Asset Management Reports 5 pct passive stake in Vanda Pharmaceuticals Inc as of Feb 15 - SEC Filing Source text: [http://bit.ly/2lnm4r7] Further company coverage:

Feb 16 2017

BRIEF-Vanda Pharmaceuticals says 2016 total revenues are expected to be nearly $146 mln

* Vanda Pharmaceuticals Inc - 2016 total revenues are expected to be approximately $146 million

Jan 09 2017

BRIEF-Vanda Pharmaceuticals qtrly loss per share $0.01

* FY2016 earnings per share view $-0.50, revenue view $147.0 million -- Thomson Reuters I/B/E/S

Nov 02 2016

BRIEF-Vanda Pharmaceuticals settles Fanapt patent litigation with Taro

* Vanda Pharmaceuticals settles Fanapt patent litigation with Taro

Oct 24 2016

Exclusive: Vanda Pharmaceuticals prepares to explore a sale - sources

Vanda Pharmaceuticals Inc , a U.S developer of medicines for the central nervous system, is preparing to consider strategic alternatives including a potential sale, according to people familiar with the matter.

Sep 22 2016

More From Around the Web

Earnings vs. Estimates